© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#Truvada

POZ March 2019 cover U=U Undetectable = Untransmitable
How Well Do U=U and PrEP Work? The CDC Updates Its Answers
Truvada (tenofovir disoproxil fumarate + emtricitabine) 101
Chart of Approved and Experimental HIV Medications

Truvada Tied to Changes in Gut-Based Immunity

Researchers studied people taking Truvada as PrEP and plan to conduct similar research on newer antiretrovirals.

Switching HIV Regimen to Biktarvy Is Safe and Effective for the Long Term

Gilead Sciences presented findings from several studies of the single-tablet antiretroviral regimen at a recent scientific meeting.

First Generic Truvada Now Available in the United States

Teva’s new version of TDF and emtricitabine doesn’t offer much of a price break, but that could come next spring.

Survey of Gay and Bi PrEP Users Finds 1 in 10 Share Their Medication

The finding from a 2018 survey raises concerns that men are accessing PrEP without receiving the recommended medical monitoring.

Southern Health Plans Often Require Preauthorization for PrEP

This bureaucratic requirement may frustrate access to PrEP in the U.S. region where the HIV epidemic is the most severe.

Case Study Outlines Evidence Indicating Man Acquired PrEP-Resistant HIV

A handful of such cases have been reported since Truvada was approved as pre-exposure prophylaxis in 2012.

Is High Cost Hindering Access to Truvada for PrEP?

Total payments for the HIV prevention pill exceeded $2 billion in 2018.

“Unprecedented” Transmission of Highly Drug-Resistant HIV in France

Researchers are surprised and concerned that a strain of HIV that is so broadly resistant to treatment even has the capacity to transmit.

STI Testing Rate for Gay Men on PrEP Is Concerningly Insufficient

This finding calls into question research that has projected that frequent testing among men on PrEP could drive down STI rates.

Taking PrEP Only For a Vacation Is an Option for Gay and Bi Men

A study found that men who started PrEP a week before a vacation and stopped a week after coming home adhered well to the daily regimen.

Major Health Insurer to Stop Covering Descovy to Prevent HIV

A low-cost generic version of Truvada as PrEP will hit the market September 30.

Prevention: PrEP 2-1-1

The 2-1-1 HIV prevention regimen offers an option for those who don’t want to take daily pills.

Long-Acting PrEP Versus Daily Truvada

Cabotegravir injections given every eight weeks as PrEP are even more effective than daily Truvada.

AVAC Launches Dynamic Global PrEP Data Tool

The HIV advocacy group has been assiduously tracking PrEP data for five years.

PrEP Cuts HIV Rate by Three Quarters in African Study

The SEARCH study included men and women at elevated risk of HIV in Kenya and Uganda.

Injectable PrEP Is Even More Effective Than Daily Truvada

The placebo-controlled trial compared injections of cabotegravir given every eight weeks versus daily Truvada as PrEP.
Advertisement
Treatment News
Blog: Undetectable = Untransmittable